Fortress Biotech, Inc. (NASDAQ:FBIO) went up by 8.35% from its latest closing price compared to the recent 1-year high of $4.46. The company’s stock price has collected 16.18% of gains in the last five trading sessions. Press Release reported 0 hour ago that Thinking about buying stock in Delta Air Lines, Scientific Games, GameStop, Vertex Pharmaceuticals, or Fortress Biotech?
Is It Worth Investing in Fortress Biotech, Inc. (NASDAQ :FBIO) Right Now?
Fortress Biotech, Inc. (NASDAQ:FBIO) scored a price-to-earnings ratio above its average ratio, recording 25.11 x from its present earnings ratio. Plus, the 36-month beta value for FBIO is at 2.18. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Fortress Biotech, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $9.80, which is -$4.34 below the current price. FBIO currently public float of 65.58M and currently shorts hold a 2.09% ratio of that float. Today, the average trading volume of FBIO was 1.34M shares.
FBIO’s Market Performance
FBIO stocks went up by 16.18% for the week, with a monthly jump of 46.30% and a quarterly performance of 53.53%, while its annual performance rate touched 133.60%. The volatility ratio for the week stands at 8.65% while the volatility levels for the past 30 days are set at 9.85% for Fortress Biotech, Inc.. The simple moving average for the period of the last 20 days is 18.91% for FBIO stocks with a simple moving average of 71.57% for the last 200 days.
Analysts’ Opinion of FBIO
Many brokerage firms have already submitted their reports for FBIO stocks, with B. Riley FBR repeating the rating for FBIO by listing it as a “Buy.” The predicted price for FBIO in the upcoming period, according to B. Riley FBR is $9 based on the research report published on December 18th of the previous year 2019.
B. Riley FBR, Inc., on the other hand, stated in their research note that they expect to see FBIO reach a price target of $10. The rating they have provided for FBIO stocks is “Buy” according to the report published on February 28th, 2018.
Rodman & Renshaw gave a rating of “Buy” to FBIO, setting the target price at $11 in the report published on July 11th of the previous year.
FBIO Trading at 36.25% from the 50-Day Moving Average
After a stumble in the market that brought FBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.58% of loss for the given period.
Volatility was left at 9.85%, however, over the last 30 days, the volatility rate increased by 8.65%, as shares surge +37.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.52% upper at present.
During the last 5 trading sessions, FBIO rose by +16.18%, which changed the moving average for the period of 200-days by +125.13% in comparison to the 20-day moving average, which settled at $3.71. In addition, Fortress Biotech, Inc. saw 69.07% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at FBIO starting from Hoenlein Malcolm, who bought 16,667 shares at the price of $18.00 back on Aug 26. After this action, Hoenlein Malcolm now owns 16,667 shares of Fortress Biotech, Inc., valued at $300,006 using the latest closing price.
ROSENWALD LINDSAY A MD, the PRESIDENT, CEO & CHAIRMAN of Fortress Biotech, Inc., bought 52,500 shares at $18.00 during a trade that took place back on Aug 26, which means that ROSENWALD LINDSAY A MD is holding 92,500 shares at $945,000 based on the most recent closing price.
Stock Fundamentals for FBIO
Current profitability levels for the company are sitting at:
- -302.54 for the present operating margin
- +66.00 for the gross margin
The net margin for Fortress Biotech, Inc. stands at -109.09. The total capital return value is set at -78.61, while invested capital returns managed to touch -42.14. Equity return is now at value -144.10, with -22.80 for asset returns.
Based on Fortress Biotech, Inc. (FBIO), the company’s capital structure generated 420.19 points at debt to equity in total, while total debt to capital is 80.78. Total debt to assets is 48.65, with long-term debt to equity ratio resting at -9.35. Finally, the long-term debt to capital ratio is 385.85.
When we switch over and look at the enterprise to sales, we see a ratio of 4.37, with the company’s debt to enterprise value settled at 0.69. The receivables turnover for the company is 3.33 and the total asset turnover is 0.20. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.43.